Q32 Bio Inc.
QTTBDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How QTTB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
bempikibart (ADX-914) | Phase 2 | Alopecia Areata | - | - |
ADX-914 | Phase 2 | Atopic Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Q32 Bio Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Q32 Bio Inc.'s (QTTB) pipeline across Phase 2. Its lead program is bempikibart (ADX-914) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Q32 Bio Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Q32 Bio Inc. (QTTB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track QTTB biotech catalysts?→
Add QTTB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Q32 Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.